Concurrent granuloma faciale and eosinophilic angiocentric fibrosis

S. A. Holme,P. Laidler,P. Holt
DOI: https://doi.org/10.1111/j.1365-2133.2005.06864.x
IF: 11.113
2005-10-01
British Journal of Dermatology
Abstract:a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab. J Clin Oncol 2003; 21:4651–3. 4 Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201–8. 5 van Doorn R, Kirtschig G, Scheffer E et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598– 601. 6 Nanney LB, Magid M, Stoscheck CM et al. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83:385–93. 7 Perez-Soler R. Can rash associated with HER1 ⁄EGFR inhibition be used as a marker of treatment outcome? Oncology 2003; 17:23–8. 8 Susman E. Rash correlates with tumour response after cetuximab. Lancet Oncol 2004; 5:647. 9 Walon L, Gilbeau C, Lachapelle JM. [Acneiform eruptions induced by cetuximab]. Ann Dermatol Venereol 2003; 130:443–6. 10 Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric antiepidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138:129–31.
What problem does this paper attempt to address?